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Abstract: Pneumatic dilatation and Heller myotomy have been thoroughly studied as the most viable 
treatment options for achalasia. The pendulum, however, is shifting to the minimally invasive approach. 
Since Inoue et al. published the experience of the first 17 cases of peroral endoscopic myotomy (POEM) in 
2010, there have been at least 5,000 cases performed worldwide and the number is increasing exponentially. 
Experts across the globe have been extending the indications to various esophageal motility disorders, 
to patients of extremes of age, sigmoidal esophagus and re-operated patients. There are a few variations 
in technique across different centers in defining the gastroesophageal junction (GEJ) and adequacy of 
myotomy, the optimal length, site of myotomy and whether the full thickness of the muscle wall should be 
cut. Large case series demonstrated its promising efficacy & reasonable complication profile. Randomized 
controlled trial in comparison with the gold standard, Heller myotomy, is ongoing. The future application 
of submucosal tunnelling technique is thrilling with its extension in tumour resection, antropyloromyotomy 
and other natural orifice transluminal endoscopic surgery (NOTES).
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Introduction
The Chicago Classification v3.0, published in 2015, 
categorized esophageal motility disorders based on findings 
in high-resolution manometry. According to a hierarchical 
approach, it further prioritized the spectrum into (I) 
“Disorders with esophagogastric junction (EGJ) outflow” 
including the different types of achalasia and EGJ outflow 
obstruction; (II) “Major disorders of peristalsis” including 
distal esophageal spasm, jackhammer esophagus and absent 
contractility; (III) “Minor disorders of peristalsis” which 
also appeared in normal controls, including ineffective 
motility and fragmented peristalsis (Figure 1). Hypertensive 
contractions were taken out from the classification as it 
showed no apparent clinical significance. The consensus 
for the next version of Chicago Classification from 
different motility societies is eagerly awaited (1). In the 
previous version of Chicago classification, the term “Spastic 
Esophageal Disorders” included Type III achalasia, diffuse 
esophageal spasm and hypercontractile (nutcracker/
jackhammer) esophagus (2). They were often studied 
together as they give rise to similar symptomatology, namely 
dysphagia, chest pain, regurgitation and heartburn. The 
overall combined prevalence is approximately 2%. Several 
pharmacological agents have been tested to decrease the 
lower esophageal sphincter pressure or reduce hypermotility 
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of the esophageal body. These include calcium channel 
blockers (e.g., nifedipine), nitrates, sildenafil in some 
smaller case studies, or even antidepressants. However, the 
evidence of efficacy is poor, and significant side effects may 
result, for instance headache, peripheral edema, flushing, 
and hypotension. More importantly, they do not halt disease 
progression (3,4). 
The incidence of achalasia is around 1 in 100,000 
population worldwide, with no gender predilection. It has 
a bimodal age distribution, with first peak at age 30s to 
40s and another after 60s. It is thought to be associated 
with functional loss of myenteric plexus ganglion cells 
in the distal esophagus and lower esophageal sphincter. 
Injection of botulinum toxin only provides temporary 
effect and it may potentially make subsequent surgery 
more difficult. Pneumatic dilatation has a successful rate of 
62–90%, associated with a small chance of perforation from 
0–16% (5). The long-term result of the randomized 
European Achalasia Trial, which compared pneumatic 
dilatation with Heller myotomy, was published in 2016. 
The authors concluded that both pneumatic dilatation 
with graded distension protocol and laparoscopic Heller 
myotomy with Dor fundoplication were equally efficient 
(82% vs. 84%) with at least 5 years of follow up. However, 
25% of patients treated with pneumatic dilatation required 
re-dilatations. In subgroup and risk factor analysis, age less 
than 40 years, pre-existing daily chest pain, a pre-treatment 
esophageal width of less than 4 cm and type III achalasia 
were identified as risk factors for treatment failure or 
requiring re-dilatation in the pneumatic dilatation group (6). 
Endoscopic myotomy was first reported by Pasricha 
et al. in 2007 in a porcine model (7). In 2010, Inoue et al. 
published the experience of the first 17 cases of peroral 
endoscopic myotomy (POEM) patients with modification 
of the steps of submucosal tunnelling by endoscopic 
submucosal dissection technique under positive pressure 
ventilation (8). The publication of a series of 500 patients 
from his center demonstrated a success rate of 91% in 1– 
2 years and 88.5% in 3 years (9). Since the introduction 
of POEM, there have been at least 5000 cases performed 
worldwide by the end of 2015 and the number is 
increasing exponentially (10). Yet, there are still a number 
of controversies on the indications, technical variations, 
efficacy & complications and application of submucosal 
tunnelling technique.
Indication
The initial inclusion criteria of the procedure by Inoue 
et al., was for proven achalasia, with age greater than 
18 years, non-sigmoidal esophagus and treatment naïve or 
uncomplicatedly treated patients (8). Recent publications 
Figure 1 Hierarchical algorithm of Chicago Classification v.3.0.
•Achalasia
•Type I: No Contractility
•Type II: ≥20% Panesophageal
Pressurization
•Type III: ≥20% Spasm (DL < 4.5 s)
IRP ≥15 mmHg & 100% failed 
peristalsis/spasm
•EGJ outflow obstructionIRP ≥15 mmHg & NOT achalasia
•Distal Esophageal Spasm (DL <4.5 s in ≥20% swallows)
•Jackhammer esophagus (≥20% DCI >8000)
•Absent contractility
IRP normal but abnormal DL/DCI or 
100% aperistasis
• Ineffective motility (≥50% ineffective swallows)
•Fragmented peristalsis
•≥50% fragmented swallows and not ineffective
IRP normal and ≥50% ineffective 
swallows
IRP normal and >50% effective 
swallows
Disorder with EGJ outflow 
obstruction
Major disorders of 
peristalsis
Minor disorders of 
peristalsis
Normal
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have shown that the inclusion criteria could be extended to 
other esophageal motility disorders, to patients of extremes 
of age, sigmoidal esophagus and re-operated patients.
Spastic esophageal motility disorder
Pharmacological therapy for spastic esophageal disorders, 
namely Type III achalasia, diffuse esophageal spasm and 
hypercontractile (nutcracker/jackhammer) esophagus has 
a relatively low efficacy with unfavourable side effects. 
The pathophysiology of this group of disease is different 
with loss of neural inhibition in achalasia and distal 
esophageal spasm and activation of cholinergic pathway 
in hypercontractile esophagus. Despite the different 
mechanisms of disease, POEM provides a logical treatment 
option equivalent to Heller myotomy with the possibility of 
extension to the proximal esophagus (11). An international 
multicentre retrospective study including 73 patients from 
11 centers showed that the efficacy in spastic achalasia 
(96.3%) and distal esophageal spasm (100%) is higher than 
that of jackhammer esophagus (70%) (12). A more recent 
meta-analysis included eight observational studies with 179 
patients showed a cumulative clinical success rate of 87% 
(Eckardt score ≤3 and/or improvement of dysphagia by 
questionnaire). Among the three spastic esophageal motility 
disorders, Type III achalasia appeared to respond best with 
92% success rate, followed by distal esophageal spasm 
(88%) and hypercontractile esophagus (72%). It concluded 
that POEM is an effective and safe procedure for spastic 
esophageal disorders. The mean submucosal tunnel and 
myotomy length was at 17.2 and 13.5 cm respectively which 
are significantly longer than that in conventional POEM as 
concluded in the white paper summary (average myotomy 
length 8–10 cm) (13,14).
Extreme of age
Achalasia has a bimodal age distribution, with the first 
peak at age 30s to 40s and another after 60 years. However, 
it affects patients in all age groups. Inoue et al. reported 
the youngest patient at 3 years old and the oldest was 
89 years old (9). Due to comorbidity and operative 
risk, many elderly patients would be left untreated or 
suggested to receive botulinum toxin injection, which is 
considered suboptimal. POEM is a kind of Natural Orifice 
Transluminal Endoscopic Surgery (NOTES), which is 
theoretically less traumatizing than traditional surgical 
approach. A recently published international multicenter 
retrospective study of 76 octogenarian patients showed 
that the adverse event rate was 14.5% while the clinical 
success rate was 90.8%. There was no 60-day mortality 
post-POEM. Technical challenge is expected to encounter 
in geriatric patients as they have (I) higher chance to have 
previous treatment, (II) longer history of the disease, leading 
to higher rate of dilated or even sigmoidal esophagus, and 
(III) they tend to have multiple comorbidities leading to 
higher operative risk and adverse events (15).
At the other extreme, achalasia is rare in paediatric 
patients, with an incidence of 0.02–0.11 per 100,000 
population. The consequence however is devastating, as 
it will result in growth retardation both physically and 
mentally. One cohort study of 27 Chinese paediatrics 
patients (6–17 years old) reported a 100% successful rate 
with a mean follow-up of more than 2 years. However, 
5 patients (19.2%) had mucosal injury or perforations. 
The authors attributed the high adverse event rate to 
technical difficulties, namely narrow lumen and fragile 
mucosa (16). Another study in India with 15 paediatric 
patients again reported 100% clinical response rate and 
6.7% mucosal injury rate (17). From technical point of 
view, the endoscopist should consider using a smaller size 
endoscope and blunt dissection for submucosal tunnelling.
Sigmoidal esophagus and patients with prior treatment
Sigmoidal esophagus is graded into S1 (where there is only 
one lumen seen in CT scan) and S2 (when tortuosity and 
U-turn leading to two lumens in CT scan). Inoue et al. 
initially only included non-sigmoidal achalasia and later 
extended the indication to more advanced cases. His first 
500 cases included 48 S1 and 29 S2 patients. The pooled 
success rate was 91% in 1–2 years and 88.5 % in 3 years 
(8,9). Hu et al. published a cohort of 32 sigmoidal achalasia 
patients (29 S1, 3 S2), clinical treatment success rate was 
96.8%. The mucosal injury rate was fairly high at 37.5%. 
Some technical advices suggested by the author included: 
(I) to design a straight path for submucosal tunnelling, e.g., 
posterior wall of esophagus along the spine; (II) to navigate 
in the tunnel perpendicular to circular muscle layer; (III) 
to expect a higher mucosal perforation rate because of 
fibrosis and limited space within the tunnel; (IV) POEM 
for sigmoidal esophagus should be performed in expert 
centers (18). 
The European Achalasia Trial concluded that both 
pneumatic dilatation with graded distension protocol and 
laparoscopic Heller myotomy with Dor fundoplication 
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were equally efficient (82% vs. 84%) with at least 5 years 
of follow up (6). However, 10–20% of patients suffered 
from persistent or recurrent of symptoms. This leads to 
the discussion on whether “salvage/rescue POEM” is 
possible and advisable. The POEM white paper summary 
published in 2014, collecting data from the International 
POEM Survey (IPOEMS) and 16 expert centers, showed 
that 43% of the operated patients had prior failed treatment 
(including botulinum injections). The consensus suggested 
that prior treatment would result in significant fibrosis in 
the submucosal layer that might result in a slower and more 
challenging dissection and increase procedure time. Despite 
the technical difficulty, the efficacy remained excellent 
(14,19,20). A recent retrospective cohort study in 13 tertiary 
centers included data of 180 patients (90 with prior Heller 
myotomy and 90 matched patients with no prior Heller 
myotomy). The technical success rate (98% vs. 100%) and 
procedure time were comparable. The clinical response was 
significantly lower in prior myotomy group (81%) vs. no 
prior myotomy group (94%). The adverse effect rate was 
not significantly different between the two groups (8% in 
prior myotomy group vs. 13% in no prior myotomy group). 
The authors concluded that although the clinical efficacy 
rate was lower, it could still be advised as the preferred 
therapeutic option due to its minimal invasiveness and 
relative safety (21). 
Technical variation
The initial procedure involves creation of a submucosal 
tunnel beginning at 13 cm proximal to the gastroesophageal 
junction (GEJ) and extending 3 cm into the proximal 
stomach. Anterior myotomy starts at 7 cm above GEJ 
and extends 2 cm distally. Completion of procedure is 
confirmed by endoscopic appearance and smooth passage of 
endoscope (8). With accumulation of experience and 
extension of indications, there are a few variations in 
technique across different centers in defining the GEJ 
and adequacy of myotomy, the optimal length, site of 
myotomy and whether the full thickness of the muscle wall 
should be cut.
Detection of GEJ & adequacy of myotomy
The gastric cardia is confirmed by (I) endoscopic 
measurements, (II) the opening up of submucosal space 
after passing the GEJ, (III) presence of palisading vessels 
(Figure 2), (IV) presence of larger calibre perforating vessels 
from the left gastric artery, (V) and the visualization of 
discolouration of submucosal tunnel from intraluminal 
view inside the stomach (14). Not all of these markers 
are accurate and clinically useful, especially in cases of 
sigmoidal esophagus where the length determined by 
endoscopy may be different from the actual distance due 
to the tortuosity of esophagus. Grimes et al. published a 
randomized controlled trial comparing the use of a second 
endoscope in detecting the transillumination from the end 
of the submucosal tunnel, viewing from a retroflex angle at 
the gastric cardia. The author concluded that using a second 
endoscope increased the procedure time by 17 min, but 
would lead to extension of the gastric myotomy length in 
34% of patients (22). Minami et al. suggested injection of 0.5 
mL of indocyanine green (ICG) into the lesser curvature 
of the gastric cardia prior to POEM as a tattoo to mark the 
end of the submucosal tunnel (19). 
Another way to predict procedure endpoint in real-
time intraoperatively is by the Endoluminal Functional 
Lumen Imaging Probe (EndoFLIP). EndoFLIP makes 
use of impedance planimetry to measure the diameter and 
cross-sectional area of EGJ. The intra-balloon pressure 
is also measured, and together, the distensibility of EGJ 
can be calculated. EGJ distensibility index (DI) was based 
on the narrowest cross-sectional area divided by the 
sum of intra-balloon pressure and intragastric pressure 
offset (23). Familiari et al. reported 23 patients using 
EndoFLIP for intraoperative evaluation of GEJ diameter 
during POEM. One patient was found to have suboptimal 
Figure 2 Endoscopic view of palisading vessels within submucosal 
tunnel at the level of gastric cardia.
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opening diameter of GEJ after initial  completion 
of  myotomy and therefore further  myotomy was 
performed (24). Teitelbaum et al. demonstrated that 
submucosal tunnelling itself would increase the DI 
from 1.2 to 3.6 mm2/mmHg and 2 cm gastric myotomy 
would further increase the DI to 7.2 mm2/mmHg. 
EndoFLIP therefore provides an intraoperative tool in 
monitoring the completeness of myotomy and the effect of 
operation (25). Teitelbaum et al. suggested an ideal 
range of DI (4.5-8.5 mm2/mmHg) can achieve optimal 
symptoms control while minimizing complication of 
reflux (26) (Figure 3).
Length and site of myotomy
The conventional POEM myotomy length averages 
8 to 10 cm. Its efficacy is reported in the literature. 
Depending on the indication, the proximal limit of the 
myotomy can be extended. In a systemic review and meta-
analysis by Khan et al. on POEM for spastic esophageal 
disease, the mean length for submucosal tunnel was 
17.2 cm and the length of myotomy was 13.5 cm (13). It 
is especially important as the pathophysiology of spastic 
esophageal disorder is caused by abnormal contractions 
in the esophageal body. The length of myotomy can be 
tailored according to preoperative investigation. Hoppo 
et al. have given examples of patients with previous 
myotomy or POEM where preoperative high resolution 
manometry or contrast study demonstrated the location 
of residual hypercontractility. The subsequent POEM can 
target at these lesions to eliminate persistent esophageal 
contractions.  The group also attempted hybrid procedure 
with laparoscopic fundoplication with long POEM 
extending to proximal esophagus in selected cases (27).
Endoscopists also vary in preference on the location 
of myotomy. The original POEM utilized an anterior/2 
o’clock/lesser curvature myotomy, mimicking the surgical 
procedure.  It also avoids disrupting the angle of His 
and therefore theoretically minimizes the chance of 
postoperative reflux. Some operators prefer the posterior/7 
o’clock/greater curvature myotomy. This path may have 
different flow-dynamics to reduce the amount of reflux 
during gastric contraction; the line of myotomy goes along 
the spine and provides a straighter submucosal tunnel in 
sigmoidal esophagus. In patients with previous anterior 
myotomy, it can provide a virgin plane (8,9,18,19). There 
is not enough evidence to recommend one over the other, 
currently it depends on endoscopists’ preference, except in 
re-do patients to avoid previous site of myotomy.
Full thickness vs. circular muscle myotomy
Inoue et al. advocated precise dissection of the circular 
muscle bundle with triangle-tip knife (8). Some other 
centers prefers full thickness myotomy because the plane 
between circular and longitudinal muscle is not always clear 
and is often obscured near the GEJ and beyond. Attempting 
to preserve the thin longitudinal muscle fibre may cause 
incomplete circular myotomy. The procedure is also 
considered to be simpler and faster (18). A retrospective 
study comparing the outcomes of full-thickness and circular 
muscle myotomy showed the mean operative time was 
significantly shorter in the full-thickness group and there 
was no increase in procedural related adverse event (28). 
Efficacy & complication
Inoue et al. has published promising long-term results of 
the first 500 cases with success rate of 91% in 1–2 years 
and 88.5 % in 3 years. Is this reproducible in other parts 
of the world? A meta-analysis involving 36 studies and 
2373 patients was published recently. Asian countries have 
dominated the number of procedures by contributing 
around 63% of the patients. The clinical success rate was 
achieved in 98%, however the follow-up period was not 
specified. Excluding gas-related complications, the most 
common procedure-related adverse event was mucosal 
injury (4.8%). 
The most concerned long-term complication of 
POEM is gastroesophageal reflux disease (GERD); unlike 
laparoscopic Heller myotomy, an anti-reflux procedure is not 
added. Depending on the parameters of GERD assessment, 
the incidence varies. In the meta-analysis, abnormal acid 
exposure in 24-hour pH monitoring is as high as 47%, while 
if only symptomatic GERD is considered, the incidence 
is 8.5%. Esophagitis occurs in 13% of patients when 
endoscopic examination is carried out (29). Familiari et al. 
reported that in 50.5% patients, abnormal acid exposure 
was found and clinically relevant GERD was evident in 
29.1%. Esophagitis and symptoms resolved completely with 
proton pump inhibitor (30).
Despite the high success rate of POEM, evidence 
from head-to-head comparison to laparoscopic Heller 
myotomy, is lacking. The recruitment of in a randomized 
controlled trial comparing endoscopic versus laparoscopic 
myotomy for achalasia has been completed. It aimed to 
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recruit 240 patients from Czech Republic, Germany, 
Italy, Netherlands and Sweden. The estimated study 
completion date would be in December 2019. Before that, 
there are several systematic reviews and meta-analyses 
based on retrospective data published in recent years. 
Talukdar et al. concluded that there were no differences 
between POEM and laparoscopic myotomy in reduction 
of Eckardt score, postoperative pain, length of hospital 
stay, adverse events and symptomatic GERD. Operative 
time was significantly lower for POEM (31). Marano et al. 
systematically reviewed data of 486 patients (196 in POEM 
group and 290 in laparoscopic myotomy group). The study 
showed that there were no differences in clinical response, 
operative time, postoperative pain and adverse event. The 
length of hospital stay was found to be shorter for POEM. 
However symptomatic gastroesophageal reflux rate was in 
favor of laparoscopic myotomy compared to POEM (32). 
It is obvious that with the current retrospective, non-
randomized nature of the included studies, the evidence 
is conflicting and inconclusive. But the clinical advantage 
of POEM is obvious, and this advantage extends beyond 
the usual indications, patient group and patients with prior 
treatments.
Future & beyond
The popularity of POEM has led to development of more 
procedures possible with submucosal tunnelling. Peroral 
endoscopic tumour resection (POET) or submucosal 
tunnelling endoscopic resection (STER) is now adopted 
in many centers to resect submucosal tumour. For tumour 
arising from the muscularis propria, direct endoscopic 
resection or snaring would result in full thickness 
perforation. Tunnelling provides safety by offsetting the 
site of mucosal entry and site of tumor resection. Size of 
the tumour would potentially limit the removal of the mass 
using this technique, though in expert centers sizable tumor 
removal has been reported (10).
A n o t h e r  p r o c e d u r e  i n s p i r e d  b y  P O E M  i s 
antropyloromyotomy (G-POEM) in the treatment of 
gastroparesis. The pathophysiology of gastroparesis included 
alteration of gastric motility and increase in pyloric tone. 
The common causes included diabetes, post-surgical 
Figure 3 EndoFLIP images comparing EGJ diameter and intraballoon pressure before and after POEM. DI before procedure was 
calculated to be 1.6 mm2/mmHg; and 5.5 mm2/mmHg after POEM. EGJ, esophagogastric junction; POEM, peroral endoscopic myotomy; 
DI, distensibility index.
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condition (such as after esophagectomy) and idiopathic. 
Gonzalez et al. reported a series of 12 patients with 
G-POEM and attained 100% technical success rate; 85% of 
patient achieved clinical improvement (33).
POEM has stimulated the field of submucosal tunnel 
endoscopy. Eleftheriadis et al. suggested some future 
perspectives in the indication of NOTES, such as 
endoscopic vagotomy, thoracoscopy, retroperitoneoscopy, 
peritoneoscopy and sympathectomy (10). The future is 
undeniably exciting.
Conclusions
Since its introduction in 2008, POEM has gained popularity 
in the treatment of achalasia and other esophageal motility 
disorders worldwide. It has provided a new option for a 
wide range of patients. Overwhelming literatures have 
demonstrated its efficacy and safety. Although comparative 
randomized control trials are still undergoing, it probably 
cannot stop the pendulum in shifting to this minimally 
invasive NOTES approach. GERD remains the weakest 
link as a complication of POEM, but after all, it is readily 
treatable by proton pump inhibitor or an additional 
fundoplication. To date, the technique is still restricted to 
limited expert centers, the generalizability and learning 
curve of the procedure is yet to be defined. The future 
application of submucosal tunnelling is thrilling. 
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